CEO Rohan Greenland reflects on the year’s major developments propelling us towards our key goals – world-leading research, vigorous advocacy, placing lived experience at the heart of all we do, and improving understanding of MS.
A new study highlights the unique housing and support needs of Australians living with MS, offering insights to improve independence and quality of life.
Researchers have found lipids (fats) in cerebrospinal fluid that may help distinguish between NMOSD and MS, as well as track disease progression and treatment effectiveness in MS.
New study reveals the 16 evidence-based recommendations to improve quality of life and manage complex disease.
People living with MS and healthcare professionals developed lifestyle recommendations to support brain health in MS, along with strategies to help people make these changes
Researchers investigated how increased cholesterol production in stem cells from people with PMS may contribute to nerve damage. They found using a cholesterol-lowering drug could reduce harmful effects, suggesting a potential new treatment approach for PMS.
Results from the D-Lay MS study, presented at ECTRIMS 2024, appeared to offer contrasting findings to PrevANZ, yet both reinforce the shared message that vitamin D, while potentially beneficial for overall health, is not a standalone treatment for MS.
CEO Rohan Greenland asks whether the Australian Government is doing enough to support MS research and neurological research more generally.
Researchers explore how an evidence-based, co-designed, digital nutrition education program empowers people with MS to make positive changes to their diet.
